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A B S T R A C T
Background: Low physical activity level is associated with poor prognosis in patients with colorectal cancer
(CRC). To increase physical activity, technology-based platforms are emerging and provide intriguing oppor-
tunities to prescribe and monitor active lifestyle interventions. The “Interval Walking in Colorectal Cancer“(I-
WALK-CRC) study explores the feasibility and eﬃcacy a home-based interval-walking intervention delivered by
a smart-phone application in order to improve cardio-metabolic health proﬁle among CRC survivors. The aim of
the present report is to describe the design, methods and recruitment results of the I-WALK-CRC study.
Methods/Results: The I-WALK-CRC study is a randomized controlled trial designed to evaluate the feasibility
and eﬃcacy of a home-based interval walking intervention compared to a waiting-list control group for phy-
siological and patient-reported outcomes. Patients who had completed surgery for local stage disease and pa-
tients who had completed surgery and any adjuvant chemotherapy for locally advanced stage disease were
eligible for inclusion. Between October 1st, 2015, and February 1st, 2017, 136 inquiries were recorded; 83
patients were eligible for enrollment, and 42 patients accepted participation. Age and employment status were
associated with participation, as participants were signiﬁcantly younger (60.5 vs 70.8 years, P < 0.001) and
more likely to be working (OR 5.04; 95%CI 1.96–12.98, P < 0.001) than non-participants.
Conclusion: In the present study, recruitment of CRC survivors was feasible but we aim to better the recruitment
rate in future studies. Further, the study clearly favored younger participants. The I-WALK-CRC study will
provide important information regarding feasibility and eﬃcacy of a home-based walking exercise program in
CRC survivors.
1. Introduction
Colorectal cancer (CRC) is the third most common cancer [1] and
the fourth most common cause of cancer-related deaths world-wide [2].
Recent evidence has demonstrated that physical activity after a CRC
diagnosis is independently associated with overall [3–8], and CRC-
speciﬁc survival [3–5,7]. Thus, CRC survivors who adhere to the cur-
rent recommendation of at least 150min of moderate intensity physical
activity per week (approx. 9 MET-hours) have been shown to have
10–40% lower CRC speciﬁc mortality and 20–50% lower overall
mortality relative to their sedentary counterparts [3–6,8].
Over the last decade, strong evidence has demonstrated positive
eﬀects of exercise interventions in cancer survivors including improved
cardiorespiratory ﬁtness [9,10], muscle function [11], body composi-
tion [12] and health related quality of life [13]. Typically, exercise-
oncology trials have prescribed supervised hospital-based training as
feasible and eﬀective health promoting strategies, but important intra-
diagnostic diﬀerences have been observed. For example, the Physical
Activity during Cancer Treatment study [14] aimed to include 300
patients with early stage breast (target n= 150) and colon cancer
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(target n= 150) exploring an 18-week supervised exercise intervention
compared to usual care. After three years, the study closed having in-
cluded more than 200 breast cancer patients [15] and only 33 colon
cancer patients, but nonetheless an improvement was observed in
physical fatigue among the CRC survivors [16]. Similar reports ob-
served positive eﬀects on cardiovascular ﬁtness [17] and metabolic
proﬁle [18] in CRC survivors, and this emphasizes the potential to
improve physiological and patient-reported outcomes in this patient
group. However, low accrual rates to traditional hospital-based exercise
interventions comprise an ongoing challenge for CRC survivors.
To address this issue, recent studies have explored the safety, fea-
sibility and eﬃcacy of various home-based strategies, including tele-
phone phone-based counseling [19] in-home treadmill-interventions
[20], and home-based programs with personal exercise trainers [18].
Simultaneously, a rapid development in smart-phone application
technology has created a novel platform for clinicians and researchers
to deliver and monitor health promoting strategies including physical
activity [21]. Recently, the smart-phone application, InterWalk [22],
was developed to disseminate an interval-walking-program to Danish
patients with diabetes. The InterWalk-application delivers a home-
based interval-walking program of interchanging fast-and-slow cycles:
3 min of fast walking followed by 3min of slow walking. This program
was based on studies showing that interval-walking was associated with
high adherence and signiﬁcant improvements in cardio-pulmonary ﬁt-
ness, plasma lipid-proﬁle, glucose metabolism and insulin sensitivity in
patients with type-2 diabetes [23,24]. These cardiometabolic health
factors are linked to the risk of disease recurrence and mortality in CRC
survivors [25,26], and are therefore important targets for life-style in-
tervention trials in this population. Accordingly, the “Interval-Walking
in Colorectal Cancer“ (I-WALK-CRC) study was designed to explore the
InterWalk-application as a health promoting intervention in CRC sur-
vivors.
2. Aims of this report
We here describe the aims, study design, and methodology of the I-
WALK-CRC study: a randomized controlled feasibility trial. Secondly,
we present the results of the recruitment procedures and compare so-
ciodemographic, socioeconomic and medical history characteristics in
study participants with eligible subjects who declined participation.
3. Study objectives and outcomes
The objectives of the I-WALK-CRC study are to explore the feasi-
bility of a smart-phone application-delivered interval-walking exercise
program in CRC survivors, as well as the eﬃcacy of the intervention to
improve cardio-metabolic health proﬁle in CRC survivors, who have
complete adjuvant treatment for non-metastatic CRC. The primary
outcome is diﬀerence in baseline-to-week12 change in VO2peak in an
intervention group (receiving 12 + 12 weeks InterWalk) compared to a
waiting-list control group (receiving 12 weeks usual care followed by
12 weeks InterWalk). Key secondary outcomes are feasibility evaluated
by inclusion rate (above 50% of eligible patients), attrition rate (below
20%); and adherence rate (above 75% of the prescribed program in
none-drop out participants). Explorative outcomes include baseline-to-
week12 changes in body weight and composition; plasma concentration
levels of cholesterols, triglycerides, insulin, glucose and inﬂammatory
cytokines; and glycemic control, by oral glucose tolerance test (OGTT).
Fig. 1. Study design and patient ﬂow.
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Additionally, we will explore 12 vs 24 weeks use of the InterWalk-ap-
plication use by evaluating changes from baseline-to-week24 in all
study outcomes in both groups.
4. Methods
The I-WALK-CRC study is a prospective, randomized controlled trial
in CRC survivors approved by the Committees of Biomedical Research
Ethics of the Capital Region of Denmark with registration number H-1-
2014-111. It is approved by the Danish Data Protection Agency, and
was registered with clinicaltrials.gov (NCT02403024). The overall
study design and ﬂow of participants is illustrated in Fig. 1.
4.1. Eligibility criteria
Patients who had completed surgery for local stage disease (UICC
Stage I-IIa) and patients who had completed surgery and any adjuvant
chemotherapy for locally advanced stage disease (UICC stage IIb-III)
were eligible for inclusion.
Exclusion criteria were: age<18 years; major surgery scheduled
within 24 weeks from inclusion; pregnancy; other current malignancy;
performance status> 1 [27]; self-reported physical activity level>
150min of moderate intensity per week; and inability to read and
understand Danish. Upon initial medical screening, participants who
were diagnosed by the study physician with an unknown and treat-
ment-requiring Type 2 diabetes (2 h glucose level higher than
11.0 mmol/l and/or level of HbA1c higher than 48mmol/mol) or un-
known cardiac conduction abnormality (ECG abnormalities) were ex-
cluded and referred to their general practitioner.
4.2. Participant recruitment
CRC patients were recruited from 5 departments (2 medical on-
cology departments and 3 surgical oncology departments) at the
Copenhagen University Hospitals: Rigshospitalet, Herlev Hospital,
Hvidovre Hospital and Bispebjerg Hospital. Patients in surveillance
within 2 years from primary CRC diagnosis were informed of the study
at clinical visits. Patients, who had undergone adjuvant chemotherapy,
were informed of the study during their ﬁnal visit at the oncology
clinic. Clinicians in the clinical departments were responsible for in-
troducing the project to possible participants by a simple 1-page re-
cruitment-leaﬂet describing the design of the study, and major exclu-
sion criteria. Patients gave consent for the I-WALK-CRC study
coordinator to contact them by telephone for full information of the
study procedures and eligibility screening.
4.3. Telephone-based eligibility screening
Upon receiving an inquiry (recruitment-leaﬂet), the study co-
ordinator contacted the potential candidate by telephone and informed
in detail about the study procedures, and performed a full eligibility
screening, which included self-reported sociodemographic and socio-
economic information (i.e. marital status, education level, employment
status, alcohol consumption, smoking habits) and medical history (i.e.
prevalence of known co-morbidities, i.e. diabetes, hypertension, car-
diovascular disease, lung disease, and whether or not patients had re-
ceived adjuvant chemo- or radiotherapy). After screening, eligible
participants were invited to meet at the study center to sign informed
consent before they were scheduled for baseline assessment.
4.4. Study assessments
Table 1 outlines the study assessment schedule. Patients met at the
laboratory after an 8-h overnight water-only fast. Before any study re-
lated test-procedures were initiated, patients underwent a thorough
medical screening by a study physician including assessment of cancer-
related information (i.e. time since diagnosis and treatment completion,
and information on tumor site). Further, medical history of comorbid-
ities and current medication were collected and followed by an objec-
tive physical examination including resting electrocardiography (ECG),
resting heart rate and blood pressure to identify any cardiac conduction
abnormalities. Upon physician approval to continue, the participants
performed the study assessments, including evaluation of fasting blood
biochemistry, glycemic control, body composition, cardiopulmonary
ﬁtness and patient reported outcomes.
Follow-up assessments were completed at Week12 and Week24 by
staﬀ members who were blinded to group allocation. Study participants
were speciﬁcally reminded before follow-up assessments not to reveal
their group allocation to the staﬀ members. The two assessments in-
cluded the same assessment schedule as the baseline test, except that
the medical screening only included measurement of resting heart rate
and blood pressure, and reports of any potential changes in medication.
4.5. Study endpoints
4.5.1. Primary endpoint - cardiopulmonary ﬁtness
Cardiopulmonary ﬁtness was determined by maximum oxygen
uptake (VO2peak) during a cardiopulmonary exercise test on a stationary
bicycle with direct measurement of oxygen uptake and carbon dioxide
excretion with gas-exchange online-measurement equipment (Cosmed
Quark, Rome, Italy). The participants carried out 3min warm up by 70
Watt followed by a step-by-step incremental test with workload in-
creasing by 20 Watt every minute until exhaustion where VO2peak, time-
to- exhaustion, peak power output, and maximum heart rate were re-
corded as test scores.
4.5.2. Secondary endpoints
Feasibility was evaluated by; I) an inclusion rate above 50% of
eligible patients; II) an attrition rate below 20% at 12 weeks; and III) an
adherence rate above 75% of the prescribed program (150min per
week) in participants who completed week-12 assessments. The study
intervention was considered feasible if all three criteria were met.
Body composition included evaluation of anthropometry and
whole-body Dual-Energy X-ray Absorptiometry (DXA) scan. The parti-
cipants' weight, height, body mass index (BMI) hip- and waist size were
measured, before body composition was analyzed using whole-body
dual-energy x-ray absorptiometry (DXA; DPX-IQ Lunar, Lunar
Corporation Madison, WI, USA). Transverse scans at 1 cm intervals
were made from head to toe measuring the absorption of x-ray beams at
two diﬀerent energy levels absorbed at a diﬀerent intensity by diﬀerent
chemical compounds (bone, fat, and fat-free mass) allowing for valid
determination of bone mass, fat mass, fat percentage and fat-free (lean)
mass.
Blood biochemistry was analyzed in fasting blood samples. After
placement of a venous elbow-catheter, a blood sample was collected to
determine fasting lipid concentrations (total, HDL, LDL-cholesterol, and
triglycerides), blood glucose, insulin and hemoglobin A1c (HbA1c), by
standard laboratory analyses. Additionally, a separate fasting blood
sample was drawn, spun and plasma was frozen (−80° C) and stored for
potential future exploratory analyses.
Glycemic control was determined by 2-h oral glucose tolerance test
(OGTT). Participants consumed 83 g glucose suspended in 300ml of
water and had a blood samples drawn after 30, 60, 90 and 120min to
measure 2-h responses in insulin, glucose and C-Peptide.
Patient reported outcome measures (PROMs) included three
questionnaires comprising the evaluation of health related quality of
life by Functional Assessment of Cancer Treatment (FACT)-C, sleep quality
by Pittsburgh Sleep Quality Index (PSQI) and exercise-motivation by
Behavioral Exercise Regulations Questionnaire (BREQ)-2.
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4.6. Randomization and group allocation
Following successful baseline assessment, the un-blinded phy-
siotherapist randomly allocated the participant to an interval walking
(IWALK) intervention group or a waiting-list control (CON) group.
Participants were stratiﬁed by treatment (adjuvant chemotherapy/no
adjuvant chemotherapy), and randomized participants remained in the
same group for the entire duration of the intervention. A computer-
generated list of random group-assignments was created by the trial
statistician using a permuted block design with allocation weight of 1:1
and stored on a password-protected web-server. Only the trial statisti-
cian and an un-blinded study physiotherapist had access to the list. The
study physiotherapist, who was not involved in any data-assessments,
performed the randomization and subsequently contacted the rando-
mized participant with information on group allocation.
4.7. Intervention and prescription
4.7.1. The InterWalk smart-phone application
On the day of the baseline test, participants were introduced to the
InterWalk smart-phone application and received thorough instructions.
If participants did not own an IOS platform smart-phone or did not wish
to download the InterWalk-application onto their own device, they
were provided with an I-POD with the InterWalk-application installed
for the duration of the study period.
The InterWalk-application consists of 2 primary functions: a test-
function (individual adaptation), and a training-function. All partici-
pants were introduced to the application and received thorough gui-
dance on how to use it. A staﬀ member helped to enter and save in-
dividual information in the application. Afterward the staﬀ member
showed how to manage the test-function and the training-function by
thoroughly reviewing a user guide together with the participant. The
InterWalk test-function [28] is an individual adaptation procedure
where participants perform an incremental walking capacity test con-
sisting of the following steps by audio-instructions: ”Stand still” for 30 s;
”walk slowly” for 2min; ”walk at medium pace” for 2min; ”walk fast”
for 2min; ”walk as fast as you can” for 1min, and ﬁnally” stand still”
for 1min to conclude the test. The InterWalk-training function here-
after instructs repeating cycles of 3min ‘slow walking’ and 3min ‘fast
walking’. The target-intensity for the diﬀerent levels were determined
from the test-function with the ”slow walking” intensity corresponding
to the average of the participants' walking speed during the ”walk
slowly” phase and the “walk at medium pace” respectively. The “fast
walking” intensity in the training function corresponds to the average
of the participants walking speed during the “walk a medium pace” and
“walk fast” phase of the test. If participants walk too fast during slow
intervals or too slow during fast intervals compared to the in-
dividualized walking paces, a speaker instructs the user to “walk slower”
or “walk faster”, respectively. Participants were instructed to perform a
new individualization test at least every third week to ensure progres-
sion in the program. All participants were supplied with a number to
the un-blinded physiotherapist if they had any problems or question
regarding the application.
4.7.2. Interval walking group
Participants randomized into the intervention I-WALK group were
prescribed interval walking by use of the InterWalk-application for a
total of 150 min per week over the full study period of 12 + 12 weeks.
It was optional how the interval walking exercise was planned and
executed over any given week with the only prescription being the
overall target volume of 150 min per week.
4.7.3. Waiting list control group
Participants randomized into the CON group were requested not to
use the InterWalk-application for the initial 12 weeks of the study
period and otherwise maintain the pre-study level of physical activity.
After week12 follow-up visit (the control period), participants in this
group received the same instructions for use of the InterWalk-applica-
tion and were prescribed 150min of interval walking per week in for
the following 12 weeks.
4.7.4. Physical activity during the study period
Throughout the study period, all participants are contacted every
fourth week by telephone by the non-blinded physiotherapist who as-
sessed physical activity level by the International Physical Activity
Questionnaires (I-PAQ) short-form.
4.8. Statistical considerations
The primary analysis will compare diﬀerence in changes in study
Table 1
Assessments schedule.
Assessments Week −1 Week 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24
Medical screening
Medical history ✕
Electrocardiography ✕
Medication ✕ ✕ ✕
Resting HR/BP ✕ ✕ ✕
Body Composition
Anthropometry ✕ ✕ ✕
DXA scan ✕ ✕ ✕
Blood Biochemistry
Fasting blood sample ✕ ✕ ✕
Glycemic Control
Oral Glucose Tolerance test ✕ ✕ ✕
Cardiopulmonary Fitness
CPET ✕ ✕ ✕
Patient Reported Outcomes
FACT-C ✕ ✕ ✕
PSQI ✕ ✕ ✕
BREC-2 ✕ ✕ ✕
Self-reported PA
IPAQ-short form ✕ ✕ ✕ ✕ ✕ ✕ ✕
Randomization ✕
HR, heart rate, BP, blood pressure, DXA, Dual Energy X-ray Absorptiometry CPET, Cardio Pulmonary Exercise Test, FACT-C, PSQI Pittsburg Sleep Quality Index, BREC-2, IPAQ-short form,
International Physical Activity Questionnaire short form.
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outcomes from baseline-to-week12 between the two treatment arms
(IWALK vs CON). For the primary outcome, VO2peak, assuming a stan-
dard deviation of 2 ml/kg/min, 16 patients in each group provided 80%
power to detect a between group diﬀerence of +2 ml/kg/min. To ac-
count for a potential attrition-rate of up to 20%, we aimed to include 20
patients in each group. The primary analysis is performed using a
random eﬀect model using study outcomes as dependent variables, the
covariates ”group”, ”time” and their interaction as ﬁxed eﬀects, and a
random eﬀect of ”patient”.
Patients who wished to drop-out of the study during the interven-
tion-periods were oﬀered to remain in the study with regard to test-
assessments. All analyses are performed as ‘intention-to-treat’ analyses,
thus all patients remained in the originally allocated treatment arms
regardless of compliance to the intervention. Potential drop-outs and
missing observations are handled by the “missing at random” principle.
4.9. Statistical analyses
For the present report, characteristics associated with participation
among eligible candidates in the present study were explored by logistic
regression analyses to compare participants with subjects who declined
participation. Logistic regression analysis was used to compare the so-
cial-demographic variables assessed at the telephone-based eligibility
screening for participation vs non-participation presented as odds ratios
with 95% conﬁdence intervals. All tests were univariate analyses, two-
sided and signiﬁcance level was set at 0.05. All statistical analyses were
performed using STATA IC 14.1.
5. Results
Between October 1st, 2015, and February 1st, 2017, we received
136 inquiries (recruitment leaﬂets) from potentially eligible CRC sur-
vivors, who were referred from one of ﬁve surgical or medical oncology
departments at Copenhagen University Hospitals (Fig. 2). From the
total number of inquiries, 38 patients were excluded prior to any elig-
ibility screening due to: ‘failed to contact’ (n= 10), ‘withdrew interest’
(n= 26) and ‘non-Danish speaking’ (n= 2), thus a total of 98 were
assessed for full telephone-based eligibility screening. Fifteen subjects
were excluded based on the following exclusion criteria: performing
more than 150min moderate intensity physical activity per week
(n=5), physically unable to perform the walking program (perfor-
mance status > 1) (n=7), had major surgery planned within the 24
weeks study-period (n=2), or was still in chemotherapy (n= 1).
Thus, a total of 83 CRC patients (61% of all inquiries) were eligible
for inclusion and were invited to participate in the study. From these,
42 patients (51%) accepted participation, and 41patients (49%) de-
clined participation. Reasons for declining participation were: ‘not in-
terested’ (n= 27), ‘did not have time’ (n= 3), ‘did not feel they could
manage study participation’ (n= 5),’ did not wish to commit to study
participation’ (n= 2), or ‘lived too far from the hospital’ (n= 4).
Following baseline-assessment, additional 3 subjects were excluded/
dropped out prior to randomization. One withdrew consent prior to
randomization, and 2 were diagnosed with previously unknown Type 2
diabetes based on elevated 2 h blood glucose level above 11.0 mmol/l
during the OGTT, and were referred to medical treatment by the pri-
mary physician. Accordingly, 39 CRC survivors were randomized to the
I-WALK or CON group. The ﬁnal participant was randomized in
January 2017, and the ﬁnal 24-week endpoint assessment was sched-
uled for September 2017.
In univariate analyses, CRC survivors who accepted participation
were younger (Age>65 years: OR 0.20 [95% CI: 0.08–0.51],
P < 0.001; Table 2), precisely they were more than a decade younger
(60.4 years vs 70.8, p < 0.001; Table 2), and more likely to be working
(Working: OR 5.04 [95% CI: 1.96–12.98], P < 0.001; Table 2) com-
pared to subjects who declined participation. Participants who accepted
participation tended to have higher educational level, but this
diﬀerence did not reach statistical signiﬁcance (p=0.092), while no
other baseline-characteristics diﬀered signiﬁcantly between partici-
pants and subjects declining participation.
6. Discussion
The I-WALK-CRC study was designed to develop and optimize ex-
ercise-interventions in patients following CRC treatment. Despite a
wealth of studies reporting a strong inverse association between phy-
sical activity level and survival in CRC survivors, this population has
been found to be among the least physically active relative to other
cancer diagnoses [29]. The I-WALK-CRC study will serve to explore the
feasibility and eﬃcacy of interval-walking exercise, delivered by a
smart-phone application in CRC survivors, and will provide initial in-
formation on the health promoting potential of a home-based, un-su-
pervised exercise intervention using on a technology-based platform.
A key component of the study rationale was that a home-based
walking exercise would appeal more to CRC survivors. We deﬁned
successful feasibility a priori to require an inclusion rate above 50% of
eligible patients. We only just reached this threshold as 42 of 83 (51%)
eligible participants were included for baseline assessment. 3 were
subsequently excluded prior to randomization and the 39 participants
were randomized over a period of approximately 16 months, which
corresponded to a rate of 2.4 participants randomized per month.
Several studies have described that recruiting CRC survivors into life-
style modiﬁcation studies can be challenging. For example, Pinto et al.
[19] implemented a variety of recruitment strategies (informational
mailings, in-clinic recruitment, and community presentations), to ex-
plore a telephone-based intervention to increase physical activity and
improve quality-of-life outcomes. The study required a sample size of
134 participants, but after 39 months, the study closed with 46 ran-
domized participants (∼1.5 per month). In comparison, the COURAGE
trial [20], a phase 2 study exploring diﬀerent exercise doses, enrolled
39 colon cancer survivors over 7 months (5.4 participants per month),
however this required information letters to be sent to over 1500 po-
tential candidates derived from cancer registries. Despite larger setups
in the above described studies, recruitment barriers seem to be present.
Danish Colorectal Cancer Group has in 2015 registered more than 600
CRC operations at the 3 recruiting surgical departments [30] which
correspond to more than 50 per month, and we only received 136 in-
quiries in 16 month which correspond to 8.5 every month. A barrier in
the I-WALK-CRC study recruitment process was the dependency of the
recruitment staﬀ at the hospitals since their commitment to the project
may vary. Many trials have found variability in the ability of staﬀ to
achieve high level of recruitment [31]. We can only speculate about
reasons for the low recruitment rate. This may stem from a lack of
perceived importance of the study question and/or lack of capacity
among recruiting staﬀ members, or evaluation conducted by clinicians
at the hospitals concerning the project's potential relevance to in-
dividual patients. Consequently, we cannot determine to what extend
the referred subjects represents the true background population of the
CRC survivors.
For the present study, in-clinic recruitment was chosen as the only
strategy based on previous experiences emphasizing the importance of
doctors' recommendation for exercise participation in cancer patients
[32,33]. Our inclusion rate was comparable to previous reports but
required recruitment from 5 departments covering most of the greater
Copenhagen area, which complicated the on-site monitoring by study
personnel and increased the risk of missing potentially eligible subjects.
One potential way to improve the recruitment barriers may be to in-
tensify on-site monitoring by including fewer recruiting departments.
This may lead to a change in the responsibility of the recruitment from
the clinical staﬀ to the study personnel, and hereby initiate a more
intensive and eﬀective recruitment.
We further hypothesized that if the intervention was more ap-
pealing to CRC survivors, the risk of selection bias would be reduced
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and the enrolled sample would comprise a more representative subset
of the background population. The mean age of all eligible subjects
were 65.5 years, which closely mirrors the estimated median age for
newly diagnosed CRC patients [34]. However, the mean age of parti-
cipants was more than a decade lower than non-participants. Elderly
patients are generally less likely to participate in exercise-oncology
trials [19,20,35], however few studies have distinguished between
candidates who are not-eligible due to various exclusion criteria (e.g.
prevalence of co-morbidities associated with advanced age), and sub-
jects who are actually eligible but elects not to participate. The true
background population comprises all eligible subjects and this group is
important to characterize in order to evaluate the external validity of a
trial. Our ﬁnding that eligible subjects who declined participation were
more than a decade older than participating subjects emphasizes the
on-going challenge to adapt these types of interventions to elderly
cancer survivors. It is possible, that the technology-based nature of our
intervention may have particularly precluded elderly subjects. How-
ever, in direct comparison the entire group invited to participate in the
COURAGE trial (n= 1,433, mean age 68) were even older (13 years)
than the population randomized (n= 39, mean age 55 years) [20],
which suggests that age-discrepancy occurs across interventions with or
without technology as a key component.
We also found diﬀerence in employment status between participants
and non-participants, with participants being more likely to work. This
is most likely associated with the age-discrepancy, and is also consistent
with previous reports [19]. Besides age and employment status, no
other background characteristics were signiﬁcantly associated with
study participation. An important observation was that we enrolled
approximately equal number of patients who had undergone surgery
only, and patients who had also undergone adjuvant chemotherapy.
Previous exercise trials have typically included most patients received
adjuvant chemotherapy and less patients who had received surgery
only. The general trend toward higher proportion of included patients
who have undergone adjuvant chemotherapy likely stems from the
motivation to use physical exercise to improve or accelerate the course
of rehabilitation after chemotherapy. However the available epide-
miological evidence have not shown diﬀerences between tumor stages
regarding the relative reduction in overall- and CRC-speciﬁc mortality
risk associated with high level of physical activity, and patients who
have only received surgery report similar (low) physical activity level as
patients who have received both surgery and adjuvant chemotherapy
[36]. From this perspective, the need to develop feasible and eﬀective
exercise-strategies in patients receiving surgery only is of equal im-
portance, but appears to be under-prioritized in current exercise-trials.
Strengths of the I-WALK-CRC study include a novel technology-
based intervention with a pragmatic aim of increasing physical activity
Fig. 2. CONSORT Diagram. Overview of recruitment results and reasons for exclusion and drop-out prior to randomization.
A. Banck-Petersen et al. Contemporary Clinical Trials Communications 9 (2018) 143–150
148
level to 150min per week as per standard guidelines. The study in-
cludes gold-standard assessments of participants cardio-metabolic
health proﬁle, including CPET, DXA-scan, OGTT, and PRO assessments,
by blinded assessors, and will serve to determine the capacity of a
walking-intervention to improve these outcomes.
Limitations of the I-WALK-CRC study may be the enrollment of a
heterogeneous population within a small sample size. While this may
broadly represent the background population, some participants may
be too ﬁt to improve signiﬁcantly from walking-based exercise, while
others may struggle to perform the prescribed program of 150min per
week. Further, in the recruiting phase we did not assess to which extend
potentially eligible CRC survivors were not informed of the study, ei-
ther due to lack of time and resources in the clinics or due to ‘pre-
screening’ by the clinical personnel. Also, we do not have self-reported
data on non-participants primary cancer site (colon or rectum cancer),
and thus, it cannot be determined if this variable was associated with
participation. Finally, we did not stratify subjects by weight/BMI,
which may be an important mediating factor, and we can only speculate
on to which extend any potential health improvements may be derived
from weight loss or a direct eﬀect of the exercise-intervention.
7. Conclusion
In the present study, recruitment of CRC survivors was feasible by
in-hospital procedures, but the trial clearly favored younger partici-
pants. The I-WALK-CRC study will provide novel and important in-
formation regarding the feasibility and eﬃcacy of home-based walking
exercise in CRC survivors, who are highly underrepresented in the
current exercise-oncology literature. These ﬁndings will contribute to
determine the relevance and perspectives of a smart-phone application
based exercise intervention can be applied as standard rehabilitation
among CRC patients. If the present study documents signiﬁcant im-
provements in cardio metabolic health outcomes, a large-scale RCT will
be required to determine if these changes translate into clinical beneﬁts.
However, exploration of diﬀerent recruitment methods is necessary to
establish a more eﬀective recruitment strategy in order to improve re-
cruitment rates.
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Table 2
Baseline characteristics of participants (n= 42) and non-participants (n= 41).
All subjects (n=83) Participants (n=42) Non-participants (n=41) Odds Ratio [95%CI] P-value
Age
Mean, range 65.5 [37;86] 60.4 [37;76] 70.8 [55;86] N.A <0.001
<65, n (%) 36 (43.4) 26 (61.9) 10 (24.4) 1.00(ref.)
≥ 65, n (%) 47 (56.6) 16 (38.1) 31 (75.6) 0.20[0.08-0.51] 0.001
Gender
Men, n (%) 39 (47.0) 21 (50.0) 18 (43.9) 1.00(ref.)
Women, n (%) 44 (53.0) 21 (50.0) 23 (56.1) 0.78[0.33-1.86] 0.578
Marital status
Married/cohabitant (%) 55 (66.3) 31 (73.8) 24 (58.5) 1.00(ref.)
Divorced/Widow (%) 28 (33.7) 11 (26.2) 17 (41.5) 0.50[0.20-1.27] 0.144
Education level
Less or ﬁnished 10th grade (%) 11 (13.2) 3 (7.1) 8 (19.5) 1.00(ref.)
High school/short higher education (%) 39 (47.0) 20 (47.6) 19 (46.3) 2.81[0.65-12.18] 0.168
Medium/long higher education (%) 33 (39.8) 19 (45.2) 14 (34.2) 3.62[0.81-16.15] 0.092
Employment status
Not workinga (%) 47 (56.6) 16 (38.1) 31 (75.6) 1.00(ref.)
Working (%) 36 (43.4) 26 (61.9) 10 (24.4) 5.04[1.96-12.98] 0.001
Smoking
Never (%) 34 (41.0) 19 (45.2) 15 (36.6) 1.00(ref.)
Earlier (%) 39 (47.0) 20 (47.6) 19 (46.3) 0.83[0.33-2.09] 0.694
Present (%) 10 (12.0) 3 (7.1) 7 (17.1) 0.34[0.07-1.54] 0.160
Units of alcohol per week
0-7 (%) 54 (65.1) 27 (64.3) 27 (65.9) 1.00(ref.)
8-14 (%) 16 (19.3) 10 (23.8) 6 (14.6) 1.67[0.53-5.23] 0.342
>14 (%) 13 (15.6) 5 (11.9) 8 (19.5) 0.63[0.18-2.16] 0.457
Diabetes
No (%) 73 (87.9) 38 (90.5) 35 (85.4) 1.00(ref.)
Yes (%) 10 (12.1) 4 (9.5) 6 (14.6) 0.61[0.16-2.36] 0.479
Hypertension
No (%) 50 (60.2) 27 (64.3) 23 (56.1) 1.00(ref.)
Yes (%) 33 (39.8) 15 (35.7) 18 (43.9) 0.71[0.29-1.72] 0.447
Cardiovascular diseaseb
No (%) 73 (87.9) 35 (83.3) 38 (92.7) 1.00(ref.)
Yes (%) 10 (12.1) 7 (16.7) 3 (7.3) 2.53[0.61-10.57] 0.202
Lung diseasec
No (%) 71 (85.5) 36 (85.7) 35 (85.4) 1.00(ref.)
Yes (%) 12 (14.5) 6 (14.3) 6 (14.6) 0.97[0.29-3.30] 0.964
Adjuvant chemotherapy
No (%) 44 (53.0) 20 (47.6) 24 (58.5) 1.00(ref.)
Yes (%) 39 (47.0) 22 (52.4) 17 (41.5) 1.55[0.65-3.70] 0.320
OR = Odds ratio, CI = Conﬁdence intervals
Signiﬁcant values in bold (p< 0.05).
a Not working includes unemployed, sick leave and retirement.
b Diagnosed cerebral apoplexy (ischemic or hemorrhagic stroke) or any other diagnosed blood cloths.
c Asthma or/and COPD.
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